6533b7d7fe1ef96bd1267a77
RESEARCH PRODUCT
Effects of a ketogenic diet in overweight women with polycystic ovary syndrome.
Maria Cristina GiaconaMassimiliano CaprioAntonino BiancoLaura MancinAntonio PaoliAntonio Paolisubject
0301 basic medicinemedicine.medical_specialtyLow carbohydrate dietlcsh:Medicine030209 endocrinology & metabolismType 2 diabetesGeneral Biochemistry Genetics and Molecular BiologyBody Mass IndexAnovulation03 medical and health sciencesFollicle-stimulating hormoneHyperinsulinemia0302 clinical medicineSex hormone-binding globulinInsulin resistanceInternal medicinemedicinePCOSHumansInsulin030109 nutrition & dieteticsbiologybusiness.industryHyperinsulinemia Ketogenic diet Ketone bodies LCKD Low carbohydrate diet Overweight PCOSResearchlcsh:Rnutritional and metabolic diseasesGeneral MedicineLuteinizing HormoneOverweightKetogenic dietmedicine.diseaseLCKDPolycystic ovaryEndocrinologyDiabetes Mellitus Type 2Hyperinsulinemia; Ketogenic diet; Ketone bodies; LCKD; Low carbohydrate diet; Overweight; PCOSbiology.proteinLean body massKetone bodiesFemaleMetabolic syndromeInsulin ResistancebusinessDiet KetogenicSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotoriePolycystic Ovary Syndromedescription
Abstract Background Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women during reproductive age. It is characterised clinically by oligo-ovulation or anovulation, hyper-androgenism, and the presence of polycystic ovaries. It is associated with an increased prevalence of metabolic syndrome, cardiovascular disease and type 2 diabetes. The onset of PCOS has been associated to several hereditary and environmental factors, but insulin resistance plays a key pathogenetic role. We sought to investigate the effects of a ketogenic diet (KD) on women of childbearing age with a diagnosis of PCOS. Methods Fourteen overweight women with diagnosis of PCOS underwent to a ketogenic Mediterranean diet with phyoextracts (KEMEPHY) for 12 week. Changes in body weight, body mass index (BMI), fat body mass (FBM), lean body mass (LBM), visceral adipose tissue (VAT), insulin, glucose, HOMA-IR, total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides (TGs), total and free testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH); dehydroepiandrosterone sulfate (DHEAs), estradiol, progesterone, sex hormone binding globulin (SHBG) and Ferriman Gallwey score were evaluated. Results After 12 weeks, anthropometric and body composition measurements revealed a significant reduction of body weight (− 9.43 kg), BMI (− 3.35), FBM (8.29 kg) and VAT. There was a significant, slightly decrease of LBM. A significant decrease in glucose and insulin blood levels were observed, together with a significant improvement of HOMA-IR. A significant decrease of triglycerides, total cholesterol and LDL were observed along with a rise in HDL levels. The LH/FSH ratio, LH total and free testosterone, and DHEAS blood levels were also significantly reduced. Estradiol, progesterone and SHBG increased. The Ferriman Gallwey Score was slightly, although not significantly, reduced. Conclusions Our results suggest that a KD may be considered as a valuable non pharmacological treatment for PCOS. Longer treatment periods should be tested to verify the effect of a KD on the dermatological aspects of PCOS. Trial registration Clinicaltrial.gov, NCT04163120, registrered 10 November 2019, retrospectively registered, https://clinicaltrials.gov.
year | journal | country | edition | language |
---|---|---|---|---|
2019-11-13 | Journal of translational medicine |